Abstract and Introduction
Purpose of Review: The interplay of asthma and coronavirus disease 2019 (COVID-19) in children is yet unknown. The purpose of this review is to determine the interplay of asthma and asthma therapeutics and COVID-19.
Recent Findings: There is no evidence to date that asthma is a risk factor for more severe COVID-19 outcomes, especially in children. There is actually some basis to suggest that children with atopic asthma may be at reduced risk of asthma exacerbations during COVID-19. The impact of asthma therapeutics on COVID-19 outcomes is unclear, but guidance is relatively uniform in recommending that those with asthma remain on current asthma medications. A focus on social determinants of health may be increasingly important during the pandemic and beyond.
Summary: Asthma in children appears to be more friend, than foe, during COVID-19.
The coronavirus disease 2019 (COVID-19) pandemic has gripped the entire world for close to the past 2 years, with over 245 million cases and close to 5 million deaths internationally as of 28 October 2021. In the United States to date, there have been more than 44 million cases and more than 715 000 deaths. While the impact of the global pandemic has been mitigated with international vaccination efforts, the impact of the pandemic, in particular among those with underlying conditions, remains an international concern. Asthma is one of the most common chronic diseases of childhood. The pandemic, and its impact on the respiratory system, has placed children and their families on 'high alert'. However, the influence of pediatric asthma on COVID-19 remains an evolving, and yet to be completely elucidated, story. The goal of this article is to review the interplay of asthma, and asthma therapeutics, with COVID-19.
Curr Opin Allergy Clin Immunol. 2022;22(2):95-100. © 2022 Lippincott Williams & Wilkins